Sangeeta Goswami, M.D., Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor (Tenured), Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor / Joint Appointment (Tenured), Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Member, Department of James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor (Tenured), Department of Immunology (Joint Appointment), The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor (Tenured), Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2009 | Baylor College of Medicine, Houston, Texas, US, Immunology, Ph.D |
| 2001 | Gauhati Medical College, Assam, IN, M.D |
Postgraduate Training
| 2013-2016 | Clinical Fellowship, Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2013 | Clinical Residency, Internal Medicine, The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania |
Licenses & Certifications
| 2021 | DEA - Researcher |
| 2019 | DEA - Practitioner |
| 2016 | American Board of Internal Medicine-Medical Oncology |
| 2016 | Texas Medical Board |
| 2015 | American Board of Internal Medicine-Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor (Tenured Track), Department of Immunology (Joint Appointment), The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2024
Assistant Professor (Tenured Track), Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Advanced Scholar, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2018
Administrative Appointments/Responsibilities
Member, Department of James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Extended Leadership Committee Member of Glioblastoma (GBM) Team, BreakThrough Cancer Initiative, Houston, Texas, 2021 - Present
Other Professional Positions
Scientific Advisory Board, Daiichi Sankyo, Basking Ridge, New Jersey, 2023 - Present
Advisory Board, Astellas/SeaGen, Houston, Texas, 2022 - Present
Consulting, Inzen Therapeutics, Watertown, Massachusetts, 2022 - Present
Postdoctoral Research Fellow, The University of Texas MD Anderson Cancer Center - Thoracic/Head and Neck Medical Oncology, Houston, TX, 2009 - 2011
Research Associate, Institute of Genomics and Integrative Biology - Immunogenetics Laboratory, New Delhi, 2002 - 2003
Junior Resident Doctor, Sacred Home Hospital and Research Center, Ulibarri, 2001 - 2002
Institutional Committee Activities
Organizing Committee, Society for Immunotherapy of Cancer (SITC) Women in Cancer Immunotherapy Network (WIN) Institute Organizers, 2024 - Present
Co-Mentor, Break Through Cancer (BTC) T32 Grant, 2024 - Present
Faculty, T32 Grant, Hematology/Oncology Fellowship Program, 2024 - Present
Search Committee, Genitourinary Medical Oncology/Radiation Oncology Chair Candidate Search Committee, 2024
Advisory Board Member, The University of Texas MD Anderson Cancer Center Epigenomics Profiling Core, 2023 - Present
Mentor, Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) Program, 2023 - Present
Member, CPRIT Translational Research Multi-Disciplinary Program (TRIUMPH) Fellowship Program, 2023 - Present
Steering Committee Member, The University of Texas MD Anderson Cancer Center Cancer Neuroscience Working Groups, 2022 - Present
Organizing Committee Member, The University of Texas MD Anderson Cancer Center Organizing Committee, 2022 Symposia on Cancer Research, 2022
Steering Committee Member, The University of Texas MD Anderson Cancer Center Myeloid Diversity Interest Group, 2021 - Present
Member, The University of Texas MD Anderson Cancer Center Scientific Research Committee (SRC), 2019 - Present
Member, The University of Texas MD Anderson Cancer Center Odyssey High Impact Research Publication Award Review Committee, 2019 - 2022
Member, The University of Texas MD Anderson Cancer Center Odyssey Fellowship Review Committee, 2019 - 2022
Member, The University of Texas MD Anderson Cancer Center Organizing Committee, 2019 Symposia on Cancer Research, 2019
Honors & Awards
| 2025 - Present | Faculty Scholar Award, The University of Texas MD Anderson Cancer Center |
| 2025 | Panelist: Precision and Advanced Immunotherapeutics, Illuminate Oncology Townhall 2.0, Mumbai, India |
| 2025 | Panelist: 6th Annual Conference of Immuno-Oncology Society of India: I-OSICON 2025, Cancer Moonshot: Indo-American Program - Challenges and Opportunities, Bhubanesar, Odisha, India |
| 2025 | Nominated, Randall Award for Excellence in Cancer Research |
| 2025 | Research Excellence, The University of Texas MD Anderson Cancer Center |
| 2024 | Nominated, Emil Frei, III Award for Excellence in Translational Research |
| 2024 | Medical Spotlight Featuring Dr. Sangeeta Goswami, MedNews Week |
| 2024 | Invited to the National Cancer Institute (NCI) Division of Cancer Biology (DCB) Workshop, National Cancer Institute |
| 2024 | Invited by the White House to be a Panelist for the Inaugural US-India Cancer Dialogue, White House |
| 2023 - Present | Inaugural Member, James P. Allison Institute |
| 2021 - 2023 | Andrew Sabin Fellowship, The University of Texas MD Anderson Cancer Center |
| 2019 - 2020 | Tang Fellowship in Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center |
| 2018 | The Parker Institute of Cancer Immunotherapy (PICI) Physician-Scientist Award, PICI |
| 2016 | American Society of Clinical Oncology (ASCO) Merit Award, ASCO |
| 2016 | Waun Ki Hong Award for Achievement in Basic Science Research, The University of Texas MD Anderson Cancer Center |
| 2007 | Outstanding Presentation-Basic Research, Department of Medicine Research Symposium, Baylor College of Medicine |
| 2006 | Best Poster Presentation, Department of Immunology, Baylor College of Medicine |
| 2005 | Best Research Proposal in Clinical Immunology, Baylor College Medicine |
| 2001 | Certification of Honor, Gauhati Medical College, India |
| 1996 | National Technical Scholarship, India |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Targeting the Eipgenetic Machinery to improve response to Immune Checkpoint Therapy. Invited. Brain Tumor Program Seminar series. Houston, Texas, US.
- 2024. The Epigenetic Regulation of T Cell Function. Invited. The Annual Center for Cancer Epigenetics Retreat (CCE’24). Houston, Texas, US.
- 2024. Epigenetic Reprogramming of the Brain Immune Microenvironment to Deter Breast Cancer Brain Metastasis Outgrowth. Conference. Houston, Texas, US.
- 2024. The Topic of Bladder Cancer. GU Lecture Series. Houston, Texas, US.
- 2024. KDM6B Improves Efficacy of PDL1 Inhibitors to Glioblastoma. Invited. MedNews Week. Virtual, Texas, US.
- 2023. Elucidating the therapeutic vulnerabilities of the epigenetic machinery to imptove responses to immune checkpoint therapy. Invited. Department of Cancer Biology Wednesday Seminar Series. Houston, Texas, US.
National Presentations
- 2025. Clinical Trials Discussion. Panelist. 7th Annual Cholangiocarcinoma Summit. Scottsdale, Arizona, US.
- 2025. Women and Work: Alternate Career Paths. Panelist. The 7th Annual Women in Cancer Immunotherapy Network (WIN) Leadership Institute (Virtual), US.
- 2025. Women and Work: Alternate Career Path. Panelist. The 7th Annual Women in Cancer Immunotherapy Network (WIN) Leadership Institute. Chicago, Illinois, US.
- 2025. Improving Immune Checkpoint Therapy Responses by Leveraging Fundamental Science and Clinical Data. Invited. The Landscapte of Cancer Research, US.
- 2025. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Blockade. Invited. Coffey-Holden Prostate Cancer Academy. Los Angeles, California, US.
- 2025. Clinical Trials Plenary entitled, Biologics and T-cell Engagers. Panelist. AACR Annual Meeting 2025. Chicago, IL, US.
- 2025. Epigenetic Modulators of Immunotherapy Response and Resistance in Bladder Cancer. Invited. 3rd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2025. 5th Annual Sylvester K12 Calabresi Symposium, US.
- 2024. Immunotherapy in Space & Time: The Tumor Microenvironment. Invited. Allison Institute Scientific Symposium. Houston, Texas, US.
- 2024. The Epigenetic Regulation of T Cell-Mediated Anti-Tumor Immunity. Conference. The Epigenetic Regulation of T Cell-Mediated Anti-Tumor Immunity. Houston, TX, US.
- 2024. Intersection of Immunology and the Epigenome in Cancer Therapeutics. Conference. Visiting Professor Series. Virtual, US.
- 2024. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. American Urological Association (AUA)-Johns Hopkins University (JHU) Greenberg Bladder Cancer Institute (GBCI) Bladder Cancer Research Symposium, "Integrating Biomarkers Into Bladder Cancer Clinical Trials". Baltimore, MD, US.
- 2024. Integrating Biomarkers Into Bladder Cancer Clinical Trials. Conference. Integrating Biomarkers Into Bladder Cancer Clinical Trials. Baltimore, MD, US.
- 2024. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. Elkin Lecture. Atlanta, GA, US.
- 2024. Medical Spotlight Featuring Dr. Sangeeta Goswami. Conference. Medical Spotlight Featuring Dr. Sangeeta Goswami. Virtual (www.mednewsweek.com), US.
- 2024. National Cancer Institute (NCI). Rockville, MD, US.
- 2023. Targeting Epigenetic Pathways to Improve Response to Immune Checkpoint Therapy. Conference.
- 2023. Global Summit on Genitourinary Malignancies. Conference. 2023 Colorado Spring GU Summit. Colorado Springs, CO, US.
- 2023. Immune Checkpoint Blockade. Conference. Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting & Pre-Conference Programs. San Diego, CA, US.
- 2023. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. James P. Allison Institute Symposium. Houston, TX, US.
- 2023. Opinions in Genitourinary Cancers: An Interactive Regional Forum. Opinions in Genitourinary Cancers: An Interactive Regional Forum. Salt Lake City, UT, US.
- 2023. Women in Cancer Immunotherapy Network (WIN) Session 1: The Art of Saying No. Conference. WIN Leadership Institute 2023. Chicago, IL, US.
- 2023. Women in Cancer Immunotherapy Network (WIN) Session 2: How to Develop Your Team. Conference. WIN Leadership Institute 2023. Chicago, IL, US.
- 2023. Women in Cancer Immunotherapy Network (WIN) Session 1: The Art of Saying No. Conference. WIN Leadership Institute 2023. Virtual, TX, US.
- 2023. Women in Cancer Immunotherapy Network (WIN) Session 2: How to Develop Your Team. Conference. WIN Leadership 2023. Virtual, TX, US.
- 2023. Targeting Epigenetic Machinery to Improve Response to Immune Checkpoint Therapy. Conference. New York Academy of Sciences (NYAS). New York, NY, US.
- 2023. Targeting Epigenetic Pathways to Improve Response to Immune Checkpoint Therapy in Genitourinary Malignancies. Conference. 2023 UT Christopher G. Wood Advances in Urologic Oncology Meeting. Austin, TX, US.
- 2023. Elucidating the Therapeutic Vulnerabilities of the Epigenetic Machinery to Improve Responses to Immune Checkpoint Therapy. Conference. Department of Cancer Biology. Houston, US.
- 2023. Updates on Bladder Cancer Treatment and Management. Conference. Faculty Speakers Bureau. Houston, TX, US.
- 2022. Immune Checkpoint Blockade. Conference. SITC’s Primer on Tumor Immunology and Cancer Immunotherapy and Session Co-Chair to the SITC 37th Annual Meeting. Boston, MA, US.
- 2022. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. The Allison Institute Seminar Series. Houston, TX, US.
- 2022. Updates on Bladder Cancer Treatment and Management. Conference. Baylor College of Medicine. Houston, TX, US.
- 2022. Breakthrough Cancer: Translating Findings from Genitourinary Cancer. Conference. Board of Visitors. Houston, TX, US.
- 2022. Targeting Immunosuppressive Myeloid Cells within the TME. Conference. Prostate Moon Shot. Virtual Meeting, TX, US.
- 2022. Immunotherapy for Kidney Cancer. Conference. 2022 Cancer Research Institute (CRI) Immunotherapy Patient Summit. Virtual Meeting, TX, US.
- 2022. Immune Checkpoint Therapy in Cancer: Current Challenges and Future Directions. Conference. Guest Lecture in Beyond the Horizon: Guest Lecture Series in Oncology, Dr. Bhubaneswar Borooah Cancer Institute (BBCI). Virtual Meeting, US.
- 2022. How to Develop Your Team. Conference. Women in Cancer Immunotherapy Network (WIN) Leadership Institute. Seattle, WA, US.
- 2022. Pathway to Becoming a Physician Scientist. Conference. Summer Experience – Career Conversations. Houston, TX, US.
- 2022. Informative Clinical Trial Platform of Longitudinal Sampling to Accelerate Development of Therapeutics for Glioblastoma. Conference. BreakThrough Cancer Summit. Kiawah, SC, US.
- 2022. Breakout Discussion, "Not Your Usual Checkpoints". Conference. Parker Institute of Cancer Immunotherapy (PICI). Montage Healdsburg, CA, US.
- 2022. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. Panel Discussion on the Division of Cancer Medicine Hematology/Oncology Fellows Research Curriculum Series. Virtual Meeting, TX, US.
- 2022. Immunotherapy. Conference. U54 Online Personalized Cancer Medicine Intensive Course. Virtual Meeting, TX, US.
- 2021. Brainstorming Retreat. Conference. CCSG Development Therapeutics Program – DT Program Retreat. Houston, TX, US.
- 2021. Pathway of Response and Resistance to Immune Checkpoint Therapy. Conference. General Internal Medicine Group at their Clinical and Research Conference. Houston, TX, US.
- 2021. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. Enjoy Science Webinar Series. Houston, TX, US.
- 2021. Bladder Cancer Updates and Management. Conference. IHA Hematology Oncology at St. Joe's Brighton (formerly IHA Hematology Oncology Consultants - Brighton). Houston, TX, US.
- 2021. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. K12 Symposium, US.
- 2020. Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies Through Reverse Translational Studies. Conference, US.
- 2020. Tumor Specific Combination Strategy for Immune Checkpoint Therapy. Conference. The Parker Institute of Cancer Immunotherapy, Fall Retreat, TN, US.
- 2020. A Pilot Study Evaluating the Clinical, Immunological, and Epigenetic Impact of EZH1/2 Inhibition in Overcoming Resistance to Immune Checkpoint Therapy (ICT) in Genitourinary Malignancies. Conference. K-12 Symposium, US.
- 2020. Differential Epigenetic Regulation of Immune Microenvironment in Lymphoid versus Myeloid Rich Tumors. Conference. Frontiers in Cancer Immunotherapy. New York, NY, US.
- 2020. Epigenetic Regulation of Immune Microenvironment. Conference. Cancer Center Support Grant (CCSG) Immunology and Cancer Genetics & Epigenetics Retreat. Houston, TX, US.
- 2019. Arid1a Mutation Plus Cxcl13 Expression Act as Combinatorial Biomarkers to Predict Responses to Immune Checkpoint Therapy in Urothelial Carcinoma, Leading Edge in Cancer Research, Symposia on Cancer Research. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Update on Bladder Cancer Treatment & Management. Conference. Doctor's Hospital of Edinburg, TX. Edinburg, TX, US.
- 2018. Immunotherapy for Bladder Cancer. Conference. MD Anderson and OncInfo Roche Preceptorship Conference. Houston, TX, US.
- 2018. Modulation of EZH2 Expression in T Cells Improves Efficacy of Anti-CTLA-4 Therapy. Conference. Melvin Samuels Lectureship. Houston, TX, US.
- 2016. Epigenetic Changes in T Cells in Response to Immune Checkpoint Blockade Therapy. Conference. The Coffey - Holden Prostate Cancer Academy (CHPCA) Meeting. Coronado, CA, US.
- 2015. Ezh2 Inhibition Affects T Cell Differentiation. Conference. First Annual Immuno-Oncology Young Investigators' Forum. Chicago, IL, US.
- 2010. Role of Inflammation in Oncogenesis. Conference. Role of Inflammation in Oncogenesis: Role of inflammatory cells in NSCLC metastasis. Keystone, CO, US.
- 2009. Divergent Roles of Airway Epithelial MMP7 ad ATRA in Experimental Asthma. Conference. AAI 96th Annual Meeting. Seattle, WA, US.
- 2008. Role of MMP7 in Asthma Pathogenesis. Conference. AAI Experimental Biology 2008 Annual Conference. San Diego, CA, US.
International Presentations
- 2025. DS3201 With Ipilimumab In Patients With Refractory Genitourinary Tumors. Poster. ESMO Congress 2025. Berlin, DE.
- 2025. Epigenetic pathways regulating responses and resistance to immune-based therapies. Invited. 19th International Congress of Immunology. Vienna, AT.
- 2025. 6th Annual Congress of I-OSICON 2025, Bhubaneswar. Invited. 6th Annual Conference of Immuno-Oncology Society of India (I-OSI). Mumbai, IN.
- 2025. Reverse Translational Strategies to Improve Patient-Specific Response to Immune Checkpoint Therapy. Immuno-Oncology-Choosing Wisely and Precisely. Bhubaneswar, IN.
- 2025. Harnessing Reverse Translational Strategies to Drive Precision Immunotherapy. Mumbia, IN.
- 2024. Inagural United States-India Cancer Dialogue. Invited. Inagural United States-India Cancer Dialogue. New Delhi, IN.
- 2024. Targeting the Epigenetic Machinery to Modulate Anti-tumor Immunity. Invited. Oxford, GB.
- 2024. Histone Lactylation(s) Orchestrate Epigenetic and Transcriptional Networks Driving CD8 T cell Function. Co-Chair, Lessons Learned from Failed Clinical Trials. Whistler, CA.
- 2024. Targeting the Epigenetic Machinery to Improve Responses to Immune Checkpoint Therapy. Invited. Kolkata, IN.
- 2024. Mechanisms of resistance to immunotherapy. Invited. Cancer Immunotherapy and Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies. Kochi, IN.
- 2024. Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance. Invited. Whistler, CA.
- 2023. 2nd International Conference on Health & Allied Sciences, ZM.
- 2022. Renal Cell Carcinoma: Current Treatment Strategies and The Role of Immune Checkpoint therapy. Guwahati, IN.
- 2021. Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies. Haryana, IN.
- 2021. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. 2021 Beijing Cancer Immunotherapy Workshop. Beijing, CN.
- 2021. Metastatic RCC: Second Line and Beyond. Bangalore, IN.
- 2021. Role of Immune Checkpoint Therapy in Cancer Treatment. Jorhat, IN.
- 2019. Modulation of Immune Checkpoint Therapy Responses by Immune Cell Inherent Epigenetic Machinery. Keystone Symposia Conference on Cancer Immunotherapy. British Columbia, CA.
- 2019. Keystone Symposia on Molecular and Cellular Biology, Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2). Whistler, CA.
Grant & Contract Support
| Date: | 2026 - 2029 |
| Title: | Advancing Cancer Careers through Education, Learning, Exploration, Research, and Training Excellence (ACCELERATE) Post-Baccalaureate Fellowship |
| Funding Source: | American Cancer Society, National (ACS) |
| Role: | Mentor |
| ID: | FP00025930 |
| Date: | 2026 - 2030 |
| Title: | Determining ARID1a Mutation-driven Pathways to Develop Biomarker-stratified Neoantigen Vaccines Plus Anti-PD-1 Therapy in Advanced Bladder Cancer |
| Funding Source: | American Cancer Society, National (ACS) |
| Role: | PI |
| ID: | FP00026829 |
| Date: | 2025 - 2028 |
| Title: | SIK2 Inhibition Enhances Anti-Tumor Immunity through ER Stress and Immune Modulation |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP 260453 |
| Date: | 2025 - 2028 |
| Title: | Determining ARID1a Mutation-driven Pathways to Develop Biomarker-stratified Neoantigen Vaccines Plus Anti-PD-1 Therapy in Advanced Bladder Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP 260554 |
| Date: | 2025 - 2030 |
| Title: | Determining KDM6A Mutation-driven Pathways to Develop Biomarker-stratified Neoantigen Vaccines Plus Anti-PD-1 Therapy in Advanced Bladder Cancer |
| Funding Source: | NCI |
| Role: | PI |
| ID: | 1 R01 CA306892 - 01 |
| Date: | 2025 - 2028 |
| Title: | Targeting CAMKK2 for the Treatment of Advanced Prostate Cancer |
| Funding Source: | NIH |
| Role: | Collaborator |
| ID: | FP00024878 |
| Date: | 2025 - 2030 |
| Title: | SIK2 in Ovarian Cancer: Regulation, ER Stress, and Immunogenic Cell Death |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00024134 |
| Date: | 2024 - 2029 |
| Title: | Histone Lactylation(s) Orchestrate Epigenetic and Transcriptional Networks Driving CD8 T Cell Metabolism and Function |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA 295824 - 01 |
| Date: | 2023 - 2028 |
| Title: | Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) Program |
| Funding Source: | NIH/NCI |
| Role: | Preceptor |
| ID: | 5 R25 CA 265800 - 02; Project: 00015483 |
| Date: | 2023 - 2028 |
| Title: | Targeting Epigenetic Machinery to Overcome Myeloid Cell-Mediated Resistance to Anti-PD-1 Therapy in GBM |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 R37 CA 279192 - 02; Project: 00014792 |
| Date: | 2023 - 2030 |
| Title: | James P. Allison Institute Assistant Member Research Support Package |
| Funding Source: | James P. Allison Institute |
| Role: | PI |
| ID: | Fund: 128234 |
| Date: | 2023 - 2025 |
| Title: | Targeting B7-H3 in Aggressive Variant Prostate Cancer |
| Funding Source: | Prostate Cancer Foundation |
| Role: | Multiple Principal Investigator |
| ID: | 22CHAL09; Project: 00014958 |
| Date: | 2022 - 2025 |
| Title: | PC210079: An Integrated Genomic Definition and Therapeutic Strategy for Androgen Indifferent Prostate Cancers |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-22-1-0259; FP00014475; Project: 00014616 |
| Date: | 2022 - 2025 |
| Title: | Development of Tertiary Lymphoid Structures (TLS) as a Biomarker to Select Patients with Bladder Cancer for Treatment with Immune Checkpoint Therapy |
| Funding Source: | The University of Texas Foundation |
| Role: | PI |
| ID: | FP00017501 Baker Hughes Foundation; Project: 00014593 |
| Date: | 2022 - 2025 |
| Title: | Informative Clinical Trial Platform of Longitudinal Sampling to Accelerate Development of Therapeutics for Glioblastoma |
| Funding Source: | BreakThrough Cancer |
| Role: | Group Leader |
| ID: | FP00015175; Project: 00014357 |
| Date: | 2021 - 2026 |
| Title: | Improving Anti-Tumor Responses to Immunotherapy Using the Combination Biomarker ARID1A and CXCL13 |
| Funding Source: | Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation |
| Role: | Multiple Principal Investigator |
| ID: | FP00012831; Project: 00013139 |
| Date: | 2021 - 2023 |
| Title: | A Study to Investigate the Role of Epigenetic Reprogramming in Improving Responses to Immune Checkpoint Therapy in Metastatic Bladder Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Andrew Sabin Family Foundation |
| Role: | PI |
| ID: | RCTS 00060089; Fund: 123930 |
| Date: | 2021 - 2023 |
| Title: | A Study to Investigate the Role of Epigenetic Reprogramming in Improving Responses to Immune Checkpoint Therapy in Metastatic Renal Cell Carcinoma |
| Funding Source: | Cancer Research Institute |
| Role: | PI |
| ID: | CRI3767; Project: 00013067 |
| Date: | 2021 - 2026 |
| Title: | Start-Up Funds |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | Fund: 123536 |
| Date: | 2021 - 2026 |
| Title: | Physician Scientist Award |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | Fund: 123569 |
| Date: | 2020 - 2021 |
| Title: | A Pilot Study Evaluating the Clinical, Immunological, and Epigenetic Impact of EZH2 Inhibition in Overcoming Resistance to Immune Checkpoint Therapy in Genitourinary Malignancies |
| Funding Source: | Paul Calabresi Clinical Oncology Research Career Development Award |
| Role: | Recipient |
| ID: | Project: 00011493 |
| Date: | 2018 - 2021 |
| Title: | Epigenetic Modulation with EZH2 Inhibition Can Overcome Resistance to Immune Checkpoint Therapy |
| Funding Source: | Emerson Collective Research Foundation |
| Role: | PI |
| ID: | RCTS: 00056312; Fund: 60065-80-121454-19 |
| Date: | 2018 - 2022 |
| Title: | Epigenetic Immunomodulation in Immunocheckpoint Therapy Responses |
| Funding Source: | Khalifa Physician Scientist Award |
| Role: | PI |
| ID: | Fund: 121373 |
Selected Publications
Peer-Reviewed Articles
- Yu, K, Basu, S, Baquer, G, Ahn, R, Gantchev, J, Jindal, S, Regan, MS, Abou-Mrad, Z, Prabhu, MC, Williams, MJ, D’Souza, AD, Malinowski, S, Hopland, K, Elhanati, Y, Stopka, SA, Stortchevoi, A, Couturier, C, He, Z, Sun, JJ, Chen, Y, Espejo, A, Chow, KH, Yerrum, S, Kao, PL, Kerrigan, BP, Norberg, L, Nielsen, D, Douville, C, Sharma, P, Giantini-Larsen, AM, Hu, J, Ayoub, G, Elharouni, D, Polk, MJ, Landivar, AM, Masud, N, Ling, AL, Triggs, D, Piranlioglu, R, Ball, A, Soni, H, Solomon, IH, Vasquez, KL, Vogelzang, J, Puduvalli, VK, Huse, J, Kim, YB, Goswami, S, Lang Jr, FF, Sharma, P. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40295505.
- Poon, C, Herbrich, SM, Chen, Y, Hossain, A, Fuller, GN, Jindal, S, Basu, S, Ledbetter, D, Macaluso, M, Phillips, LM, Gumin, J, He, Z, Parker Kerrigan, BC, Singh, S, Singh, P, Zaman, MF, Ng Tang, D, Goswami, S, Lang Jr, FF, Sharma, P. Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome. Cancer Immunology Research 13(6):804-820, 2025. e-Pub 2025. PMID: 40131028.
- Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Tannir NM, Futreal A, Wang L, Sharma P. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat Commun 16(1):1846, 2025. e-Pub 2025. PMID: 39984485.
- Moussa MJ, Khandelwal J, Wilson NR, Malikayil KL, Surasi DS, Bathala TK, Lin Y, Rao P, Tamboli P, Sircar K, Ajufo H, Elsayes KM, Shah A, Johns AC, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. J Immunother Cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
- Moussa, MJ, Khandelwal, J, Wilson, NR, Malikayil, KL, Surasi, DS, Bathala, TK, Lin, Y, Rao, P, Tamboli, P, Sircar, K, Ajufo, HO, Elsayes, KM, Shah, AY, Johns, AC, Goswami, S, Hasanov, E, Jonasch, E, Msaouel, P, Campbell, M, Alhalabi, O, Tannir, NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. Journal for immunotherapy of cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
- Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Futreal A, Wang L, Tannir NM, Sharma P. Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma. Res Sq, 2024. e-Pub 2024. PMID: 39606482.
- Goswami S. Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer. e-Pub 2024.
- Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 49:100866, 2024. e-Pub 2024. PMID: 39403573.
- Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, Natarajan SM, Trujillo-Ocampo A, Im JS, Goswami S. Histone lactylation drives CD8(+) T cell metabolism and function. Nat Immunol 25(11):2140-2151, 2024. e-Pub 2024. PMID: 39375549.
- Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus 11(1):150-158, 2024. e-Pub 2024. PMID: 39307587.
- Anandhan S, Herbrich SM, Goswami S, Guan B, Chen Y, Macaluso M, Jindal S, Natarajan SM, Andrewes S, Xiong L, Nagarajan A, Basu S, Tang DN, Liu J, Min J, Maitra A, Sharma P. TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Nat Commun 15(1):5291, 2024. e-Pub 2024. PMID: 38987547.
- Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell M, Zurita-Saavedra A, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid and/or Rhabdoid Dedifferentiation after Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2024. PMID: 38035767.
- Hanif IH, Abdelrahim S, Al Shaarani M, Lu H, Ahmad R, Goswami S, Abudayyeh A. Immune Checkpoint Therapy–Induced Lupus Nephritis. Kidney Int Rep 9(5):1534-1537, 2024. e-Pub 2024. PMID: 38707799.
- Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D, Puduvalli VK, Huse J, Beroukhim R, Kim YSB, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Antonio Chiocca E, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Investigative needle core biopsies for multi-omics in Glioblastoma. medRxiv, 2023. e-Pub 2023. PMID: 38234840.
- Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
- Goswami S, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso M, He Z, Jindal S, Lang FF Jr, Basu S, Sharma P. Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nature Cancer 4(10):1455-1473, 2023. e-Pub 2023. PMID: 37653141.
- Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell M, Shah AY, Corn P, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641), 2022. e-Pub 2022. PMID: 35442707.
- Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
- Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7):e002850, 2021. e-Pub 2021. PMID: 34326169.
- Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci 1489(1):30-47, 2021. e-Pub 2021. PMID: 33184911.
- Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol 11:621591, 2021. e-Pub 2021. PMID: 33747934.
- Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
- Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12(548), 2020. e-Pub 2020. PMID: 32554706.
- Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2020. PMID: 31873309.
- Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res 7(11):1803-1812, 2019. e-Pub 2019. PMID: 31466995.
- Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818, 2018. e-Pub 2018. PMID: 29905573.
- Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology 5(11):e1234570, 2016. e-Pub 2016. PMID: 27999749.
- Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
- Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2013. PMID: 23204236.
- Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Song LZ, Redding D, Singh B, Sur S, Woodruff P, Dong C, Corry DB, Kheradmand F. Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol 10(5):496-503, 2009. e-Pub 2009. PMID: 19329997.
- Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13(5):567-9, 2007. e-Pub 2007. PMID: 17450149.
- Zhao L, Leung JK, Yamamoto H, Goswami S, Kheradmand F, Vu TH. Identification of P311 as a potential gene regulating alveolar generation. Am J Respir Cell Mol Biol 35(1):48-54, 2006. e-Pub 2006. PMID: 16484684.
- Sharma M, Batra J, Mabalirajan U, Goswami S, Ganguly D, Lahkar B, Bhatia NK, Kumar A, Ghosh B. Suggestive evidence of association of C-159T functional polymorphism of the CD14 gene with atopic asthma in northern and northwestern Indian populations. Immunogenetics 56(7):544-7, 2004. e-Pub 2004. PMID: 15378299.
Invited Articles
- Goswami S, Sharma P. Loss of ARID1A 'loops' in STING. Trends Immunol 45(8):568-570, 2024. e-Pub 2024. PMID: 39060141.
- Goswami S. KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy. Nat Cancer 4(10):1408-1409, 2023. e-Pub 2023. PMID: 37700093.
- Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40(3):249-251, 2022. e-Pub 2022. PMID: 35290784.
- Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med 24(2):123-124, 2018. e-Pub 2018. PMID: 29414936.
- Goswami S, Sharma P. Genetic biomarker for cancer immunotherapy. Science 357(6349), 2017. e-Pub 2017. PMID: 28751597.
- Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. Prostate 77(2):123-144, 2017. e-Pub 2017. PMID: 27679977.
- Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 22(2):117-20, 2016. e-Pub 2016. PMID: 27111907.
Review Articles
- Pauken, KE, Alhalabi, O, Goswami, S, Sharma, P. Neoadjuvant immune checkpoint therapy. Cancer cell 43(4):623-640, 2025. e-Pub 2025. PMID: 40118048.
- Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol 25(12):2186-2199, 2024. e-Pub 2024. PMID: 39587347.
- Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy—current perspectives and future directions. Cell 186(8):1652-1669, 2023. e-Pub 2023. PMID: 37059068.
- Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol 23(2):106-120, 2023. e-Pub 2023. PMID: 35697799.
- Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. e-Pub 2021. PMID: 33811120.
Abstracts
- Goswami S. KDM6B Mediated Epigenetic Reprogramming of Intratumoral Myeloid Cells Improves Response to Immune Checkpoint Therapy in Glioblastoma. CICON 2023 7th International Cancer Immunotherapy Conference, 2023. e-Pub 2023.
- Wang J, Campbell MT, Shah AY, Goswami S, Msaouel P, Alhalabi O, Hahn AW, Kovitz CA, Jana BRP, Arajo JC, Gao J, Zurita AJ, Jonasch E, Corn PG, Tannir NM. A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases. J Clin Oncol 41(6), 2023. e-Pub 2023.
- Jiang C, Alhalabi O, Haro-Silerio J, Qiao W, Shah AY, Siefker-Radtke AO, Gao J, Goswami S, Alva AS, Koshkin VS, Guo C, Campbell MT. Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV). J Clin Oncol 41(16_Suppelment), 2023. e-Pub 2023.
- Shah AY, Campbell MT, Tidwell R, Siefker-Radtke AO, Goswami S, Alhalabi O, Adriazola AC, Shaw L, Ye Y, Chen J, Yan X, Wang L, Gao J. A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer. J Clin Oncol 40(16), 2022. e-Pub 2022.
- Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell MT, Shah AY, Wang J, Jonasch E, Arajo JC, Wang J, Gao J, Goswami S, Msaouel P, Tannir NM. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol 40(6), 2022. e-Pub 2022.
- Andreev-Drakhlin A, Shah AY, Adriazola AC, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Siefker-Radtke AO, Goswami S, Xiao L, Venkatesan AM, Campbell MT. Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). J Clin Oncol 39(6), 2021. e-Pub 2021.
- Msaouel P, Gao J, Yuan Y, Siefker-Radtke AO, Jonasch E, Goswami S, Zurita AJ, Campbell MT, Shah AY, Corn PG, Ramos C, Yan X, Chin C, Der-Torossian H, Tannir NM. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting, 2021. e-Pub 2021.
- Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang Z, Natarajan S, Xiong L, Guan B, Singh S, Saci A, Allison JP, Galsky MD, Sharma P. Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer. Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting, 2021. e-Pub 2021.
- Siddiqui B, Gheeya JS, Goswamy R, Subudhi SK, Gao J, Shah AY, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Siefker-Radtke AO, Sharma P, Tannir N. Immune Checkpoint Therapy (ICT) re-Challenge after immune-related adverse events (irAEs) in genitourinary cancers: safety and efficacy. European Society for Medical Oncology (ESMO) Virtual Congress Meeting, 2020. e-Pub 2020.
- Goswami S, Chen J, Zhao H, Zhang X, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade therapy. American Association of Clinical Research (AACR) Annual Meeting, 2016. e-Pub 2016.
- Goswami S, Zhang X, Hao Z, Allison JP, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade therapy. American Society of Clinical Oncology (ASCO) Annual Meeting, 2016. e-Pub 2016.
- Goswami S, Shi L, Sharma P. Ezh2 affects T cell differentiation. Immuno-Oncology Young Investigator Forum, 2015. e-Pub 2015.
- Chen L, Goswami S, Yi X, Byers L, Diao L, Roybal J, Ungewiss C, Peng D, Wang J, Wistuba I, Chen L, Ullrich S, Heymach J, Kurie J, Win XF, Gibbons D. A big role in tumor immune microenvironment of a small non-coding RNA: microRNA-200. Cancer Immunol Res 3(10_Supplement), 2015. e-Pub 2015.
- Gibbons DL, Chen L, Goswami S, Cortez MA, Ahn YH, Byers LA, Win L, Diao L, Wang J, Roybal J, Ungewiss C, Antonia SJ, Mediaville-Varela M, Suraokar MB, Welsh J, Chen L, Wistuba II, Heymach J, Kurie JM, Qin FXF. Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer metastasis. American Society of Clinical Oncology (ASCO) Annual Meeting, 2014. e-Pub 2014.
- Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Wistuba II Goswami S, Cortiz MA, Welsh J, Kurie JM, Heymach J. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers. American Society of Clinical Oncology (ASCO) Annual Meeting, 2014. e-Pub 2014.
- Gibbons DL, Chen L, Goswami S, Ahn YH, Byers LA, Diao L, Wang J, Cortez A, Roybal J, Welsh J, Zhang X, Dwyer D, Yi X, Lieping C, Wistuba I, Heymach JV, Kurie JM, Qin FXF. microRNA-200 regulates tumor cell PD-L1 expression to control lung cancer metastasis. Clin Cancer Res 20(2_Supplement), 2014. e-Pub 2014.
- Massarelli E, Erez B, Goswami S, Kurie JM. CXCR2 inhibition decreases invasion and metastasis of a KRAS/p53-mutant lung adenocarcinoma cell line in vitro and in vivo. Cancer Res 72(8_Supplement), 2012. e-Pub 2012.
- Goswami S, Ahn YH, Lin W, Mediavila-Varela M, Zhang X, Baruch E, Dwyer DW, Ungewiss C, Patel MP, Antonia S, Qin XF, Kurie JM. miR-200 suppression in tumor cells promotes metastasis by trigging intra-tumoral CD8+ T cell anergy. IDIBELL Cancer Conference on Metastasis and Angiogenesis, 2011. e-Pub 2011.
- Goswami S, Lin W, Dwyer D, Qin XF, Kurie JM. Role of Inflammatory Cells in Lung Cancer Metastasis. Keystone Symposium, 2010. e-Pub 2010.
- Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Sur S, Woodruff C, Dong C, Corry DB, Kheradmand F. Divergent roles of airway epithelial MMP7 and retinoic acid in experimental asthma. J Immunol 182(1):Supplement, 2009. e-Pub 2009.
- Goswami S, Barranco W, Greenlee KJ, Seryshev AB, Corry DB, Kheradmand F. Role of matrix-metalloprotease-7 in a model of experimental asthma. FASEB J, 2008. e-Pub 2008.
- Goswami S, Barranco W, Lee SL, Grudo A, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema. National Student Research Forum (NSRF), 2007. e-Pub 2007.
- Goswami S, Barranco W, Lee SL, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema. J Immunol, 2007. e-Pub 2007.
- Lee SL, Goswami S, Grumelli S, Corry DB, Kheradmand F. Elastin derived peptide mediate autoimmune basis for smoking-induced emphysema in human. American Association of Immunologists (AAI), 2006. e-Pub 2006.
Book Chapters
- Sharma A, Campbell M, Yee C, Goswami S, Sharma P. Immunotherapy of Cancer. In: Clinical Immunology: Principles and Practice. 5th Edition, 1033-1048.e1, 2019.
- Goswami S, Allison JP, Sharma P. Novel and Other Cancer Topics of Interest: Immuno-Oncology. In: The MD Anderson Manual of Medical Oncology: Third Edition. Third Edition. The McGraw-Hill Companies, Inc, 995-1002, 2016.
- Sharma P, Subudhi SK, Peggs K, Goswami S, Gao JJ, Quezada S, Allison JP. Chapter 13: Cancer Immunotherapy. In: Cancer Medicine 9th Edition. 9th Edition. Hong WK, Bast R, Hait WN Wiley, 2015.
- Massarelli E, Goswami S, Piha-Paul S. Section 1: Targets by Organ Site: Head and Neck Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2014.
Patient Reviews
CV information above last modified August 15, 2025